Rossana Calderon Moreno1, Ana Navas-Acien2, Esteban Escolar3, David M Nathan4, Jonathan Newman5, John F Schmedtje6, Denisse Diaz3, Gervasio A Lamas3, Vivian Fonseca7. 1. Columbia University Division of Preventive Medicine and Nutrition, New York, New York. 2. Columbia University Mailman School of Public Health, New York, New York. 3. Department of Medicine, Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida. 4. Diabetes Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 5. Department of Medicine, New York University School of Medicine, New York, New York. 6. Roanoke Heart Institute PLC, Roanoke, Virginia. 7. Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
Abstract
CONTEXT: For decades, there has been epidemiologic evidence linking chronic toxic metal exposure with cardiovascular disease, suggesting a therapeutic role for metal chelation. Given the lack of compelling scientific evidence, however, the indications for metal chelation were never clearly defined. To determine the safety and efficacy of chelation therapy, the National Institutes of Health funded the Trial to Assess Chelation Therapy (TACT). TACT was the first double-blind, randomized, controlled trial to demonstrate an improvement in cardiovascular outcomes with edetate disodium therapy in patients with prior myocardial infarction. The therapeutic benefit was striking among the prespecified subgroup of patients with diabetes. DESIGN: We review the published literature focusing on the atherogenic nature of diabetes, as well as available evidence from clinical trials, complete and in progress, of metal chelation with edetate disodium therapy in patients with diabetes. RESULTS: The TACT results support the concept that ubiquitous toxic metals such as lead and cadmium may be modifiable risk factors for cardiovascular disease, particularly in patients with diabetes. CONCLUSIONS: The purpose of this review is to discuss the potential mechanisms unifying the pathogenesis of atherogenic factors in diabetes with toxic metal exposure, and the potential role of metal chelation.
CONTEXT: For decades, there has been epidemiologic evidence linking chronic toxic metal exposure with cardiovascular disease, suggesting a therapeutic role for metal chelation. Given the lack of compelling scientific evidence, however, the indications for metal chelation were never clearly defined. To determine the safety and efficacy of chelation therapy, the National Institutes of Health funded the Trial to Assess Chelation Therapy (TACT). TACT was the first double-blind, randomized, controlled trial to demonstrate an improvement in cardiovascular outcomes with edetate disodium therapy in patients with prior myocardial infarction. The therapeutic benefit was striking among the prespecified subgroup of patients with diabetes. DESIGN: We review the published literature focusing on the atherogenic nature of diabetes, as well as available evidence from clinical trials, complete and in progress, of metal chelation with edetate disodium therapy in patients with diabetes. RESULTS: The TACT results support the concept that ubiquitous toxic metals such as lead and cadmium may be modifiable risk factors for cardiovascular disease, particularly in patients with diabetes. CONCLUSIONS: The purpose of this review is to discuss the potential mechanisms unifying the pathogenesis of atherogenic factors in diabetes with toxic metal exposure, and the potential role of metal chelation.
Authors: Natalia V Solenkova; Jonathan D Newman; Jeffrey S Berger; George Thurston; Judith S Hochman; Gervasio A Lamas Journal: Am Heart J Date: 2014-07-22 Impact factor: 4.749
Authors: Eliseo Guallar; M Inmaculada Sanz-Gallardo; Pieter van't Veer; Peter Bode; Antti Aro; Jorge Gómez-Aracena; Jeremy D Kark; Rudolph A Riemersma; José M Martín-Moreno; Frans J Kok Journal: N Engl J Med Date: 2002-11-28 Impact factor: 91.245
Authors: Marc G Weisskopf; Nitin Jain; Huiling Nie; David Sparrow; Pantel Vokonas; Joel Schwartz; Howard Hu Journal: Circulation Date: 2009-09-08 Impact factor: 29.690
Authors: Ana Navas-Acien; Elizabeth Selvin; A Richey Sharrett; Emma Calderon-Aranda; Ellen Silbergeld; Eliseo Guallar Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Anna Z Pollack; Lindsey Sjaarda; Katherine A Ahrens; Sunni L Mumford; Richard W Browne; Jean Wactawski-Wende; Enrique F Schisterman Journal: PLoS One Date: 2014-03-28 Impact factor: 3.240